Fig. 1 · Structure

Documents & Downloads

Alectinib (CH5424802)

Cat. No. A11134 CAS 1256580-46-7

ALK Inhibitor

Alectinib (CH5424802) is a potent, selective, and orally available ALK inhibitor with a unique chemical scaffold, showing preferential antitumor activity against cancers with gene alterations of ALK.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
ALK(F1174L) IC50 1nM
ALK IC50 1.9nM
ALK(R1275Q) IC50 3.5nM
INSR IC50 550nM
KDR IC50 1.4μM
Abl IC50 >5μM
EGFR IC50 >5μM
FGFR2 IC50 >5μM
HER2 IC50 >5μM
IGF-1R IC50 >5μM
JAK1 IC50 >5μM
Kit IC50 >5μM
Met IC50 >5μM
PDGFRβ IC50 >5μM
Src IC50 >5μM
Akt1 IC50 >5μM
Akt2 IC50 >5μM
Akt3 IC50 >5μM
AuroraA IC50 >5μM
CDK1 IC50 >5μM
CDK2 IC50 >5μM
MEK1 IC50 >5μM
PKA IC50 >5μM
PKCα IC50 >5μM
PKCβ1 IC50 >5μM
PKCβ2 IC50 >5μM
Raf-1 IC50 >5μM

27 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
BaF3 IC50 > 1000 nM Cytotoxicity against mouse BA/F3 cells assessed as cell viability after 72 hrs by MTS assay [PMID: 26568289]
BaF3 IC50 169 nM Inhibition of EML4-ALK L1152R mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay [PMID: 26568289]
BaF3 IC50 2 nM Inhibition of wild type EML4-ALK (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay [PMID: 26568289]
BaF3 IC50 2 nM Inhibition of EML4-ALK C1156Y mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay [PMID: 26568289]
BaF3 IC50 2 nM Inhibition of EML4-ALK S1206Y mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay [PMID: 26568289]
BaF3 IC50 207 nM Inhibition of EML4-ALK G1202R mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay [PMID: 26568289]
BaF3 IC50 3 nM Inhibition of EML4-ALK F1174L mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay [PMID: 26568289]
BaF3 IC50 72 nM Inhibition of EML4-ALK 1151Tins mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay [PMID: 26568289]
BaF3 IC50 9 nM Inhibition of EML4-ALK G1269A mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay [PMID: 26568289]
BaF3 IC50 90 nM Inhibition of EML4-ALK L1196M mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay [PMID: 26568289]
KARPAS-299 IC50 15 nM Antiproliferative activity against human KARPAS299 cells after 72 hrs by SRB/CCK-8 assay [PMID: 27131066]
KARPAS-299 IC50 3 nM Antiproliferative activity against human KARPAS-299 cells harbouring ALK by CellTiter-Glo luminescent cell viability assay [PMID: 34402300]
KARPAS-299 IC50 3 nM Antiproliferative activity against human KARPAS299 cells after 96 hrs by cell counting assay [PMID: 22225917]
KARPAS-299 IC50 47 nM Antiproliferative activity against ALK-positive human KARPAS-299 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay [PMID: 34176264]
Kelly EC50 434 nM Antiproliferative activity against human Kelly cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay [PMID: 26568289]
NB1 IC50 4.5 nM Antiproliferative activity against human NB1 cells harbouring ALK by CellTiter-Glo luminescent cell viability assay [PMID: 34402300]
NCI-H2228 IC50 53 nM Antiproliferative activity against human NCI-H2228 cells harbouring ALK by CellTiter-Glo luminescent cell viability assay [PMID: 34402300]
NCI-H2228 IC50 6.5 nM Cytotoxicity in human NCI-H2228 cells harboring EML4-fused ALK variant 3 incubated for 72 hrs by alamar blue reagent based assay [PMID: 31425908]
NCI-H3122 IC50 17.4 nM Antiproliferative activity against human NCI-H3122 cells after 72 hrs by SRB/CCK-8 assay [PMID: 27131066]

19 records · Scroll to view more

Alectinib (CH5424802) Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Alectinib (CH5424802) from 3 published references. In vitro models include ALK1510-c4 cells; NCI-H2228 parental cells.

Alectinib (CH5424802) In Vitro Studies

In ALK1510-c4 cells, Alectinib exposure at 1000 nM for 24 h transiently increased relative HER2 phosphorylation by ~25%. Exposure to Alectinib at 1000 nM for 9 days increased relative EGFR phosphorylation in ALK1510-c4 cells. In NCI-H2228 parental cells treated with Alectinib for 8 days, the cell viability IC50 was 219.6 nM. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Transient HER2 phosphorylation increase in ALK1510-c4 cells

Cell-based study · ALK1510-c4 cells [1]

ALK1510-c4 cells exposed to Alectinib at 1000 nM for 24 h showed a transient increase in relative HER2 phosphorylation of ~25%.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Relative HER2 phosphorylation levelsRelative phosphorylation of HER2 ~25%[1]

Literature-Reported Treatment Conditions

Treatment concentration
1000 nM
Exposure duration
24 h
Method
exposure
Vehicle
dimethyl sulfoxide (DMSO; Sigma-Aldrich)
Methods and source locations

Compound reported in the paper: Alectinib

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Drugs and reagents (S10); Results > Evaluation of ErbB signaling in alectinib-induced ALK1510-c4 DTP cells treated with the pan-HER inhibitor dacomitinib (S120); Fig. 3 legend (S192)

Relative HER2 phosphorylation levels: Relative HER2 phosphorylation levels; comparator: nontreated controls — Results > Evaluation of ErbB signaling in alectinib-induced ALK1510-c4 DTP cells treated with the pan-HER inhibitor dacomitinib (S120); Fig. 3 legend (S192)

Cell viability response in NCI-H2228 parental cells

Cell-based study · NCI-H2228 parental cells [2]

NCI-H2228 parental cells were treated with Alectinib for 8 days. The cell viability IC50 was 219.6 nM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell viabilityIC50 219.6 nM[2]

Literature-Reported Treatment Conditions

Exposure duration
for 8 days
Method
drugs were added
Vehicle
dimethyl sulfoxide
Reported limits
Not stated in the sentences used: dose.
Methods and source locations

Compound reported in the paper: Alectinib

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > DTP cells escape ALK-TKI-induced cell death through activation of FGFR signaling (S10); Methods > Drugs and reagents (S108); Methods > Anti-cancer compound library screen of NCI-H2228 cells (S118); Methods > Cell proliferation assay (S122, S123, S124); Fig. 1 legend (S196)

cell viability: cell viability; comparator: vehicle — Results > DTP cells escape ALK-TKI-induced cell death through activation of FGFR signaling (S10); Methods > Cell proliferation assay (S123)

Increased relative EGFR phosphorylation in ALK1510-c4 cells

Cell-based study · ALK1510-c4 cells [1]

ALK1510-c4 cells were exposed to Alectinib at 1000 nM for 9 days. Relative EGFR phosphorylation, measured as phosphorylated EGFR divided by total EGFR, increased.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
relative phosphorylation (phosphorylated EGFR [pEGFR]/total EGFR)relative EGFR phosphorylation approximately six-fold[1]

Literature-Reported Treatment Conditions

Treatment concentration
1000 nM
Exposure duration
9 days
Method
exposure
Vehicle
dimethyl sulfoxide (DMSO; Sigma-Aldrich)
Methods and source locations

Compound reported in the paper: Alectinib

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Drugs and reagents (S10); Results > Evaluation of ErbB signaling in alectinib-induced ALK1510-c4 DTP cells treated with the pan-HER inhibitor dacomitinib (S122, S124); Fig. 3 legend (S192)

relative phosphorylation (phosphorylated EGFR [pEGFR]/total EGFR): relative phosphorylation (phosphorylated EGFR [pEGFR]/total EGFR); comparator: nontreated controls — Results > Evaluation of ErbB signaling in alectinib-induced ALK1510-c4 DTP cells treated with the pan-HER inhibitor dacomitinib (S122)

Alectinib (CH5424802) In Vivo Studies

In the EA2 orthotopic tumor model in C57BL/6 mice, Alectinib was administered at 20 mg/kg daily by oral gavage. The comparison of Alectinib with diluent isolated the compound effect and showed marked tumor shrinkage. [3]

Tumor shrinkage in an orthotopic mouse model

Animal study · EA2; C57BL/6 mice; orthotopic tumors [3]

In the EA2 orthotopic tumor model in C57BL/6 mice, Alectinib at 20 mg/kg was administered daily by oral gavage. The comparison of Alectinib with diluent isolated the compound effect, showing marked tumor shrinkage.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
tumor volume is presented as the fold change from the initial pre-treatment measurementReported result Marked tumor shrinkage was induced by alectinib in all three models[3]

Conditions shared by the study groups

Route
oral gavage
Treatment course
daily
Vehicle
H2O
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Alectinib 20 mg/kgdiluentMarked tumor shrinkage was induced by alectinib in all three models[3]
Alectinib 20 mg/kg
Model: EA2; C57BL/6 mice; orthotopic tumors
Methods and source locations

Compound reported in the paper: Alectinib

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Adaptive immunity is required for durable alectinib responses (S19, S22, S24, S26, S27, S28); Methods > Orthotopic mouse model of EML4-ALK lung cancer (S128)

tumor volume is presented as the fold change from the initial pre-treatment measurement: tumor volume is presented as the fold change from the initial pre-treatment measurement; comparator: diluent — Results > Adaptive immunity is required for durable alectinib responses (S22, S28)

Alectinib 20 mg/kg · Results > Adaptive immunity is required for durable alectinib responses (S22, S27)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1256580-46-7
Applications ALK Inhibitor
Formula C30H34N4O2
Molecular Weight 482.6
Synonyms CH-5424802
SMILES
CCC1=C(C=C2C(=C1)C(=O)C3=C(C2(C)C)NC4=C3C=CC(=C4)C#N)N5CCC(CC5)N6CCOCC6

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 0.5 mg/mL (1.03 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Alectinib (CH5424802) Research References

  1. [1] Fujimura T, Furugaki K, Mizuta H, et al. Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer. NPJ Precis Oncol (2024). PMID: 39551860 DOI: 10.1038/s41698-024-00757-w Source material
  2. [2] Furugaki K, Fujimura T, Mizuta H, et al. FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes. NPJ Precis Oncol (2023). PMID: 37880373 DOI: 10.1038/s41698-023-00462-0 Source material
  3. [3] Kleczko EK, Hinz TK, Nguyen TT, et al. Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity. NPJ Precis Oncol (2023). PMID: 36739466 DOI: 10.1038/s41698-023-00355-2 Source material

Added to your cart

View Cart Checkout
Loading...